Generex Biotechnology Receives Purchase Order for Generex Oral-lyn(TM) for Algerian Market

Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced it has received its first purchase order for Generex Oral-lyn(TM) from Continental Pharm Laboratories, a pharmaceutical products distributor in Algeria. The order consists of 10,000 canisters of Generex Oral-lyn(TM) which will be filled by the Company's Middle Eastern branch office, Generex MENA (Middle East and Northern Africa), located in Dubai Healthcare City.

"We are pleased that the first order for Generex Oral-lyn(TM) has come so quickly on the heels of the launch in Algeria last week," said Bill Abajian, Sr. Executive Advisor, Global Business Development and Licensing for the Company. "It is a testament to the enthusiasm demonstrated by the endocrinologists to introduce Generex Oral-lyn(TM) to their patients' treatment paradigm and to the education and training strategy tailored to the region and implemented by the Generex MENA office."

Generex MENA is responsible for over 20 countries and has relationships with over 31 distributors for each of the various product lines and territories who have already begun commercializing the Company's confectionary product lines, and out of those countries, eight are actively pursuing regulatory approval for Generex Oral-lyn(TM), the Company's proprietary oral insulin spray product, and have filed the Generex Oral-lyn(TM) dossier with their respective regulatory authorities.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world. Antigen Express, Inc. is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases. For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

The Generex Biotechnology Corp. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Generex Biotechnology Corp.

CONTACT:  American Capital Ventures, Inc.
Investor Relations Contact:
Howard Gostfrand
1-877-918-0774
Beckerman Public Relations
Media Contact:
Angelene Taccini
201-465-8024

Related terms: advisor, africa, algeria, biotechnology, business, clinical, diabetes, distributor, drugs, dubai, ecuador, executive, forecasts, healthcare, india, lebanon, market, middle east, nasdaq, pharmaceuticals, product development, products, securities, technology, training